NEW YORK (GenomeWeb News) – Personalized medicine startup Medomics said this week that it is in discussions with various undisclosed entities to raise $3 million to $4 million to further develop and market its gene sequencing-based diagnostic test for mitochondrial diseases.

Medomics, based in Azusa, Calif., expects to receive a $1 million investment from an undisclosed corporate co-investor if it can raise $2 million to $3 million in financing from additional investors, Steve Sommer, president and founder of Medomics, told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.